Frontiers in Immunology · 2023 · 19 citations · 48 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyMonoclonal AntibodiesBispecific AntibodiesBispecific Antibody TherapyCancer ImmunotherapyNatural Killer Cell BiologyNatural Killer Cell FunctionNatural Killer Cell RegulationAntibody-dependent Cell-mediated CytotoxicityAntibody-dependent Cellular CytotoxicityBispecific Antibody DiscoveryCd19-directed Bispecific AntibodiesCd20-directed Bispecific AntibodiesFragment Antigen-binding ConstructsNatural Killer Group 2, Member DSingle-chain Bispecific Antibodies
The activating receptor natural killer group 2, member D (NKG2D) represents an attractive target for immunotherapy as it exerts a crucial role in cancer immunosurveillance by regulating the activity of cytotoxic lymphocytes. In this study, a panel of novel NKG2D-specific single-chain fragments variable (scFv) were isolated from naïve human antibody gene libraries and fused to the fragment antigen binding (Fab) of rituximab to obtain [CD20×NKG2D] bibodies with the aim to recruit cytotoxic lymphocytes to lymphoma cells. All bispecific antibodies bound both antigens simultaneously. Two bibody constructs, [CD20×NKG2D#3] and [CD20×NKG2D#32], efficiently activated natural killer (NK) cells in co-cultures with CD20+ lymphoma cells. Both bibodies triggered NK cell-mediated lysis of lymphoma cells and especially enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) by CD38 or CD19 specific monoclonal antibodies suggesting a synergistic effect between NKG2D and FcγRIIIA signaling pathways in NK cell activation. The [CD20×NKG2D] bibodies were not effective in redirecting CD8+ T cells as single agents, but enhanced cytotoxicity when combined with a bispecific [CD19×CD3] T cell engager, indicating that NKG2D signaling also supports CD3-mediated T cell activation. In conclusion, engagement of NKG2D with bispecific antibodies is attractive to directly activate cytotoxic lymphocytes or to support their activation by monoclonal antibodies or bispecific T cell engagers. As a perspective, co-targeting of two tumor antigens may allow fine-tuning of antibody cancer therapies. Our proposed combinatorial approach is potentially applicable for many existing immunotherapies but further testing in different preclinical models is necessary to explore the full potential.
48
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · Nature Medicine · 2000 · 2.7K citations
Medicine, Cancer Biology, Oncology +15
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk et al. · New England Journal of Medicine · 2022 · 1.1K citations · Full text
Medicine, Hematology, Immunology +17
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Ralf C. Bargou, Eugen Leo, Gerhard Zugmaier et al. · Science · 2008 · 1.1K citations
Life Sciences, Immunology, Oncology +17